According to the World Health Organization, dengue represents one of the 10 biggest global health threats and it is critical to have access to a safe and effective vaccine candidate that can reduce the devastating impact of dengue fever in endemic regions, Panacea Biotec said in a BSE filing.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3hYh3hS
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» Panacea Biotec completes Phase I/II study of DengiAlI vaccine
0 comments:
Post a Comment